KR101069735B1 - 미세소관 형성 저해제로서 유용한 벤조페논 티아졸 유도체 및 이의 제조 방법 - Google Patents
미세소관 형성 저해제로서 유용한 벤조페논 티아졸 유도체 및 이의 제조 방법 Download PDFInfo
- Publication number
- KR101069735B1 KR101069735B1 KR1020090018700A KR20090018700A KR101069735B1 KR 101069735 B1 KR101069735 B1 KR 101069735B1 KR 1020090018700 A KR1020090018700 A KR 1020090018700A KR 20090018700 A KR20090018700 A KR 20090018700A KR 101069735 B1 KR101069735 B1 KR 101069735B1
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- phenyl
- triazol
- trimethoxybenzoyl
- formula
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
Description
화합물 516 |
화합물 615 |
화합물 624 |
화합물 625 |
화합물 631 |
화합물 646 |
화합물 647 |
화합물 648 |
|
용해도 (mg/mL) |
0.5 | 23.3 | 14.9 | 11.0 | 25.4 | 29.1 | 12.1 | 12.5 |
실험군(n=6) | 용량/일 | 투여방법 | 체중변화(%) | IR(%) | 사망 동물수 |
대조군 | - | - | +18.4 | - | 0/6 |
AC7700 | 100 ㎎/㎏ | q4d×4 (i.p.) | +13.2 | 48 % | 2/6 |
화합물 516 | 5 ㎎/㎏ | q4d×4 (i.p.) | +15.2 | 36 % | 2/6 |
실험군(n=6) | 용량/일 | 투여방법 | 체중변화(%) | IR(%) | 사망 동물수 |
대조군 | - | - | +24.5 | - | 0/6 |
AC7700 | 100 ㎎/㎏ | q4d×4 (i.p.) | +22.8 | 34 % | 0/6 |
화합물 624 | 5 ㎎/㎏ | q4d×4 (i.p.) | +25.7 | 28 % | 0/6 |
10 ㎎/㎏ | +14.7 | 64 % | |||
화합물 625 | 5 ㎎/㎏ | q4d×4 (i.p.) | +28.9 | 21 % | 0/6 |
10 ㎎/㎏ | +24.5 | 43 % | |||
화합물 631 | 5 ㎎/㎏ | q4d×4 (i.p.) |
+24.8 | 23 % | 0/6 |
10 ㎎/㎏ | +26.7 | 20 % | |||
20 ㎎/㎏ | +20.9 | 37 % |
실험군(n=6) | 용량/일 | 투여방법 | 체중변화(%) | IR(%) | 사망 동물수 |
대조군 | - | - | -3.4 | - | 0/6 |
AC7700 | 80 ㎎/㎏ | q4d×4 (i.p.) | +5.5 | 66 % | 1/6 |
화합물 624 | 5 ㎎/㎏ | q4d×4 (i.p.) |
+1.8 | 12 % | 0/6 |
7.5 ㎎/㎏ | +3.2 | 63 % | 0/6 | ||
10 ㎎/㎏ | +6.6 | 69 % | 0/6 |
실험군(n=7) | 용량/일 | 투여방법 | 체중변화(%) | IR(%) | 사망 동물수 |
대조군 | - | - | +5.4 | - | 0/7 |
AC7700 | 80 ㎎/㎏ | q4d×4 (i.p.) | +2.6 | 64 % | 0/7 |
화합물 624 | 5 ㎎/㎏ | q4d×4 (i.p.) |
-1.7 | 39 % | 0/7 |
7.5 ㎎/㎏ | +1.7 | 61 % | 0/7 | ||
10 ㎎/㎏ | -1.2 | 71 % | 0/7 |
실험군(n=6) | 용량/일 | 투여방법 | 체중변화(%) | IR(%) | 사망 동물수 |
대조군 | - | - | -15.3 | - | 0/6 |
AC7700 | 80 ㎎/㎏ | q4d×4 (i.p.) | +7.8 | 55 % | 0/6 |
화합물 624 | 5 ㎎/㎏ | q4d×4 (i.p.) |
-11.8 | 21 % | 0/6 |
7.5 ㎎/㎏ | +2.9 | 46 % | 0/6 | ||
10 ㎎/㎏ | +4.3 | 68 % | 0/6 |
실험군(n=6) | 용량/일 | 투여방법 | 체중변화(%) | IR(%) | 사망 동물수 |
대조군 | - | - | +30.0 | - | 0/6 |
AC7700 | 80 ㎎/㎏ | q4d×4 (i.p.) | +22.4 | 80 % | 0/6 |
화합물 624 | 5 ㎎/㎏ | q4d×4 (i.p.) |
+26.2 | 41 % | 0/6 |
7.5 ㎎/㎏ | +26.0 | 73 % | 0/6 | ||
10 ㎎/㎏ | +20.6 | 82 % | 0/6 |
Claims (7)
- 제 1 항에 있어서, 하기 화합물로부터 선택된 화합물, 이의 이성질체, 약제학적으로 허용가능한 이의 염, 이의 수화물 또는 이의 용매화물:화합물 615N-(4-(3-(1H-1,2,4-트리아졸-1-일)-4-(3,4,5-트리메톡시벤조일)페닐)티아졸-2-일)-2-아미노아세트아마이드화합물 624(S)-N-(4-(3-(1H-1,2,4-트리아졸-1-일)-4-(3,4,5-트리메톡시벤조일)페닐)티아졸-2-일)-2-아미노-3-메틸부탄아마이드화합물 625(S)-N-(4-(3-(1H-1,2,4-트리아졸-1-일)-4-(3,4,5-트리메톡시벤조일)페닐)티아졸-2-일)-2-아미노-3-페닐프로판아마이드화합물 631N-(4-(3-(1H-1,2,4-트리아졸-1-일)-4-(3,4,5-트리메톡시벤조일)페닐)티아졸-2-일)-2-(다이메틸아미노)아세트아마이드화합물 646(S)-N-(4-(3-(1H-1,2,4-트리아졸-1-일)-4-(3,4,5-트리메톡시벤조일)페닐)티아졸-2-일)피롤리딘-2-카복사마이드화합물 647(S)-N-(4-(3-(1H-1,2,4-트리아졸-1-일)-4-(3,4,5-트리메톡시벤조일)페닐)티아졸-2-일)-2-아미노-4-메틸펜탄아마이드화합물 648(S)-N-(4-(3-(1H-1,2,4-트리아졸-1-일)-4-(3,4,5-트리메톡시벤조일)페닐)티아졸-2-일)-2-아미노-3-사이클로헥실프로판아마이드화합물 652N-(4-(3-(1H-1,2,4-트리아졸-1-일)-4-(3,4,5-트리메톡시벤조일)페닐)티아졸-2-일)-2-아미노-3-메틸부탄아마이드화합물 653(R)-N-(4-(3-(1H-1,2,4-트리아졸-1-일)-4-(3,4,5-트리메톡시벤조일)페닐)티아졸-2-일)-2-아미노-3-메틸부탄아마이드
- 제 1 항에 있어서, (S)-N-(4-(3-(1H-1,2,4-트리아졸-1-일)-4-(3,4,5-트리메톡시벤조일)페닐)티아졸-2-일)-2-아미노-3-메틸부탄아마이드, 이의 이성질체, 약제학적으로 허용가능한 이의 염, 이의 수화물 또는 이의 용매화물.
- 제 1 항에 있어서, (S)-N-(4-(3-(1H-1,2,4-트리아졸-1-일)-4-(3,4,5-트리메톡시벤조일)페닐)티아졸-2-일)-2-아미노-3-페닐프로판아마이드, 이의 이성질체, 약제학적으로 허용가능한 이의 염, 이의 수화물 또는 이의 용매화물.
- 삭제
- 제 1 항의 화합물, 이의 이성질체, 약제학적으로 허용 가능한 이의 염, 이의 수화물 또는 이의 용매화물을 유효성분으로 하고, 약제학적으로 허용되는 부형제 또는 담체를 포함하는, 악성종양 치료용 약제학적 조성물.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20080027820 | 2008-03-26 | ||
KR1020080027820 | 2008-03-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090102639A KR20090102639A (ko) | 2009-09-30 |
KR101069735B1 true KR101069735B1 (ko) | 2011-10-04 |
Family
ID=41114435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090018700A KR101069735B1 (ko) | 2008-03-26 | 2009-03-05 | 미세소관 형성 저해제로서 유용한 벤조페논 티아졸 유도체 및 이의 제조 방법 |
Country Status (15)
Country | Link |
---|---|
US (1) | US8362267B2 (ko) |
EP (1) | EP2272845B1 (ko) |
JP (1) | JP5378499B2 (ko) |
KR (1) | KR101069735B1 (ko) |
CN (1) | CN101981029B (ko) |
AU (1) | AU2009229709B2 (ko) |
BR (1) | BRPI0906248B8 (ko) |
CA (1) | CA2719243C (ko) |
DK (1) | DK2272845T3 (ko) |
ES (1) | ES2536794T3 (ko) |
HU (1) | HUE025268T2 (ko) |
MX (1) | MX2010010561A (ko) |
PL (1) | PL2272845T3 (ko) |
PT (1) | PT2272845E (ko) |
WO (1) | WO2009119980A2 (ko) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019517506A (ja) * | 2016-07-29 | 2019-06-24 | チョン クン ダン ファーマシューティカル コーポレーション | 血管破壊剤を含む肝臓癌治療用の組成物 |
US9980953B2 (en) | 2016-09-26 | 2018-05-29 | Chong Kun Dang Pharmaceutical Corp. | Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivatives as a VDA and topoisomerase inhibitor |
CN107163011B (zh) * | 2017-05-27 | 2019-10-01 | 上海应用技术大学 | 3-(3,4,5-三甲氧基苯甲酰)-苯并呋喃类微管蛋白抑制剂及其制备方法和用途 |
AU2018308312B2 (en) * | 2017-07-26 | 2021-05-27 | Chong Kun Dang Pharmaceutical Corp. | Composition for preventing or treating cancer comprising a vascular disrupting agent and immune checkpoint inhibitor |
KR102216772B1 (ko) | 2018-05-18 | 2021-02-17 | 주식회사 종근당 | 혈관차단제 및 탁산 화합물을 포함하는 암 예방 또는 치료용 조성물 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005009940A1 (en) | 2003-07-24 | 2005-02-03 | Leo Pharma A/S | Novel aminobenzophenone compounds |
WO2006063585A1 (en) | 2004-12-13 | 2006-06-22 | Leo Pharma A/S | Triazole substituted aminobenzophenone compounds |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101053558A (zh) * | 2003-03-05 | 2007-10-17 | 细胞基因公司 | 二苯基乙烯化合物及其用途 |
KR100932093B1 (ko) | 2006-09-27 | 2009-12-16 | 주식회사종근당 | 미세소관 형성 저해제로서 유용한 벤조페논 유도체 |
-
2009
- 2009-03-05 CA CA2719243A patent/CA2719243C/en active Active
- 2009-03-05 DK DK09725663.0T patent/DK2272845T3/en active
- 2009-03-05 PL PL09725663T patent/PL2272845T3/pl unknown
- 2009-03-05 ES ES09725663.0T patent/ES2536794T3/es active Active
- 2009-03-05 JP JP2011501712A patent/JP5378499B2/ja active Active
- 2009-03-05 HU HUE09725663A patent/HUE025268T2/en unknown
- 2009-03-05 BR BRPI0906248A patent/BRPI0906248B8/pt active IP Right Grant
- 2009-03-05 KR KR1020090018700A patent/KR101069735B1/ko active IP Right Grant
- 2009-03-05 AU AU2009229709A patent/AU2009229709B2/en active Active
- 2009-03-05 MX MX2010010561A patent/MX2010010561A/es active IP Right Grant
- 2009-03-05 WO PCT/KR2009/001095 patent/WO2009119980A2/ko active Application Filing
- 2009-03-05 PT PT97256630T patent/PT2272845E/pt unknown
- 2009-03-05 US US12/934,521 patent/US8362267B2/en active Active
- 2009-03-05 CN CN200980110763.9A patent/CN101981029B/zh active Active
- 2009-03-05 EP EP09725663.0A patent/EP2272845B1/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005009940A1 (en) | 2003-07-24 | 2005-02-03 | Leo Pharma A/S | Novel aminobenzophenone compounds |
WO2006063585A1 (en) | 2004-12-13 | 2006-06-22 | Leo Pharma A/S | Triazole substituted aminobenzophenone compounds |
Also Published As
Publication number | Publication date |
---|---|
BRPI0906248B1 (pt) | 2020-01-21 |
EP2272845A2 (en) | 2011-01-12 |
PL2272845T3 (pl) | 2015-08-31 |
DK2272845T3 (en) | 2015-05-04 |
HUE025268T2 (en) | 2016-02-29 |
MX2010010561A (es) | 2010-10-25 |
WO2009119980A3 (ko) | 2009-12-17 |
US20110021582A1 (en) | 2011-01-27 |
JP2011515461A (ja) | 2011-05-19 |
BRPI0906248A2 (pt) | 2016-10-25 |
WO2009119980A2 (ko) | 2009-10-01 |
AU2009229709A1 (en) | 2009-10-01 |
EP2272845B1 (en) | 2015-03-04 |
CA2719243C (en) | 2013-06-25 |
BRPI0906248B8 (pt) | 2021-05-25 |
PT2272845E (pt) | 2015-06-01 |
CA2719243A1 (en) | 2009-10-01 |
JP5378499B2 (ja) | 2013-12-25 |
ES2536794T3 (es) | 2015-05-28 |
AU2009229709B2 (en) | 2011-12-08 |
CN101981029A (zh) | 2011-02-23 |
US8362267B2 (en) | 2013-01-29 |
KR20090102639A (ko) | 2009-09-30 |
CN101981029B (zh) | 2014-04-02 |
EP2272845A4 (en) | 2014-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10370364B1 (en) | Substituted chromenes for treatment of fibrosis or non-alcoholic steatohepatitis | |
WO1998014451A1 (en) | Fused pyrazole derivative and process for its preparation | |
JP5695200B2 (ja) | 複素環アミノベルバミン誘導体、その調製方法及び使用 | |
KR101069735B1 (ko) | 미세소관 형성 저해제로서 유용한 벤조페논 티아졸 유도체 및 이의 제조 방법 | |
KR101138840B1 (ko) | 이마티닙 다이클로로아세트산염 및 이를 포함하는 항암제 조성물 | |
JP4707393B2 (ja) | 抗癌化合物 | |
JP5701387B2 (ja) | ベルバミンのジカルボキシミド誘導体、その調製方法及び使用 | |
AU2016304331B2 (en) | Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent. | |
WO2022115753A1 (en) | Merged scaffold taf1 inhibitors | |
CN114790177A (zh) | 新型Hedgehog信号通路抑制剂 | |
CN116802175A (zh) | 新型谷氨酰胺类似物 | |
EP3116882A2 (en) | Compounds for eradicating or inhibiting proliferation of cancer stem cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20140716 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20150824 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20160715 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20170627 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20180718 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20190625 Year of fee payment: 9 |